Yutiq
Pronunciation: pronunciation varies by local usage.
- Generic name
- fluocinolone acetonide
- Brand names
- YUTIQ
- Drug class
- Corticosteroid intravitreal implant
- Form
- Preloaded applicator with non-bioerodible intravitreal implant
- Route
- Intravitreal injection
- Legal status
- Prescription-only medicine
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What fluocinolone acetonide is and how it works
Yutiq is a non-bioerodible intravitreal implant containing 0.18 mg fluocinolone acetonide, a corticosteroid. It is placed into the vitreous of the eye by an ophthalmologist and releases medicine slowly for about 36 months. (1)
It is used for chronic non-infectious uveitis affecting the posterior segment of the eye. The implant is placed and monitored entirely by an ophthalmology team; patients do not handle the product.
Mechanism of action: how fluocinolone acetonide works
Fluocinolone acetonide is a corticosteroid delivered continuously from a non‑bioerodible implant into the vitreous humor, suppressing inflammation in chronic non‑infectious uveitis. (1)
What fluocinolone acetonide is used for
Chronic non-infectious uveitis affecting the posterior segment
Yutiq is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1)
Before taking fluocinolone acetonide
Do not take / not appropriate for
- Do not receive Yutiq if you have an active or suspected ocular or periocular infection. (all indications) (1)
- Do not receive Yutiq if you have a known hypersensitivity to fluocinolone acetonide or any other component of the implant. (all indications) (1)
Tell your clinician about
- Any eye infection or suspected infection, recent eye surgery, or injury.
- If you are pregnant, planning pregnancy, or breastfeeding.
- Any other eye conditions or treatments you are using, including steroid eye drops.
- Your full medical history and all current medicines.
How to take fluocinolone acetonide
- Yutiq is administered as a single intravitreal injection by an ophthalmologist in a sterile office-based procedure using a preloaded applicator.
- The implant releases fluocinolone acetonide for approximately 36 months. Patients do not self-administer or handle the implant.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
Since Yutiq is a single implanted device that provides continuous treatment, there is no dosing schedule to miss. Contact your ophthalmologist if you have any concern about the implant’s function.
Overdose
Because Yutiq is a single implant administered by an ophthalmologist, overdose is not expected. Contact the treating ophthalmologist if you have any concerns. (1)
Side effects
The most common adverse reactions are cataract and increased intraocular pressure. Because the implant is placed inside the eye, serious eye complications can occur and require urgent evaluation.
Cataract
What to notice: Clouding of the natural lens of the eye; over half of eyes with a natural lens may develop cataract during the 3‑year implant period.
What to do: Your ophthalmologist will monitor and schedule surgery if needed. (1)
Elevated intraocular pressure
What to notice: Eye pressure rise of 10 mmHg or more; may require pressure‑lowering eye drops or other treatment.
What to do: Regular pressure checks are scheduled by the ophthalmology team. (1)
Endophthalmitis or severe eye inflammation
What to notice: Eye pain, worsening redness, sensitivity to light, decreased or blurred vision, possibly floaters.
What to do: Contact the ophthalmologist immediately or seek emergency eye care. (1)
Retinal detachment or implant migration
What to notice: Sudden increase in floaters, flashes of light, a curtain over vision, or change in vision.
What to do: Seek immediate ophthalmologic evaluation. (1)
Serious warnings
Endophthalmitis — emergency
Symptoms: Severe eye pain, redness, light sensitivity, or decreased vision.
Action: Contact ophthalmologist immediately; endophthalmitis is a medical emergency. (1)
Elevated intraocular pressure/glaucoma — urgent
Symptoms: Eye discomfort, blurred vision, halos around lights, or no symptoms at all.
Action: Attend scheduled tonometry checks; report any symptoms promptly. (1)
Retinal detachment — emergency
Symptoms: New floaters, flashes, curtain‑like vision loss.
Action: Seek immediate eye examination. (1)
Implant migration — urgent
Symptoms: Vision change or eye discomfort; migration possible if posterior capsule is torn.
Action: Your ophthalmologist will monitor and manage this risk. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Other ocular corticosteroids | Additive corticosteroid effects possible, such as increased intraocular pressure or cataract progression. | Tell your ophthalmologist about all eye treatments, including drops; the team will adjust as needed. (1) |
| Systemic medications | No systemic drug‑interaction studies have been conducted; systemic exposure from the implant is minimal. | Inform your ophthalmologist of all medicines you take. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
There are no adequate human studies. The decision to use Yutiq during pregnancy should be made by the patient and her specialist, weighing potential risks. (1)
Breastfeeding
It is unknown whether fluocinolone from the implant passes into breast milk. Discuss with your care team. (1)
Monitoring
Before starting
- Confirm the diagnosis of chronic non‑infectious uveitis affecting the posterior segment.
- Rule out any active ocular or periocular infection.
- Assess posterior lens capsule integrity, because a tear or absence increases the risk of implant migration.
- Inform the patient of risks including cataract, elevated intraocular pressure, and the need for regular follow‑up.
During treatment
- Immediately after injection: check optic nerve head perfusion.
- Within 30 minutes: measure intraocular pressure (tonometry).
- Within 2–7 days: perform biomicroscopy examination.
- Ongoing: regular monitoring of intraocular pressure and cataract development for the 3‑year implant life.
Storage
Storage instructions are provided in the product packaging. Yutiq is stored and handled exclusively by the ophthalmology team before use.
Professional information
Clinician‑facing context only. Refer to the full prescribing information for complete indication, safety, and monitoring details.
United States
Indication: Chronic non‑infectious uveitis affecting the posterior segment
Dose summary: Yutiq is a single 0.18 mg fluocinolone acetonide intravitreal implant administered by an ophthalmologist via a preloaded applicator under aseptic conditions.
Renal context: Systemic exposure from the intravitreal implant is minimal; renal or hepatic impairment is not expected to require dose modification. Consult the full prescribing information for specific guidance. (1)
Hepatic guidance
Minimal systemic exposure; no hepatic dose adjustment expected. Use local product information and specialist judgement.
Overdose note
Overdose is unlikely with a single implant. If multiple implants are suspected, contact the treating ophthalmologist. No specific overdose information is provided in the label. (1)
Frequently asked questions
How long does one implant last?
The implant releases fluocinolone acetonide for about 36 months from a single office‑based injection. (1)
What symptoms after the injection are urgent?
Eye pain, worsening redness, sensitivity to light, decreased or blurred vision—these could signal infection, pressure rise, or retinal detachment. Contact your ophthalmologist immediately. (1)
Will it affect my lens or eye pressure?
Over half of study eyes with a natural lens developed a cataract, and elevated eye pressure is common. The ophthalmology team schedules regular pressure checks and eye exams for the life of the implant. (1)
Is the injection done at home?
No, it is an in‑office sterile procedure performed by an ophthalmologist, with checks immediately, at 30 minutes, and within a week. (1)
What is the mechanism of action of fluocinolone acetonide?
Fluocinolone acetonide is a corticosteroid delivered continuously from a non‑bioerodible implant into the vitreous humor, suppressing inflammation in chronic non‑infectious uveitis. (1)
What is the generic name of Yutiq?
The generic name is fluocinolone acetonide. It is sold under brand names including YUTIQ. (1)
What class of drug is fluocinolone acetonide?
Yutiq is classed as: Corticosteroid intravitreal implant. (1)
References
- YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, Alimera Sciences, label revised 2026-01U.S. Food and Drug Administration · United States · accessed 2026-08-08 · source 1
- FLUOCINOLONE ACETONIDE OIL [BRYANT RANCH PREPACK] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Fluocinolone Topical — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- Fluocinolone Acetonide — FDA approval record (Drugs@FDA ANDA089124)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- fluocinolone acetonide — RxNorm normalized drug concept (RXCUI 4461)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient fluocinolone acetonide names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Fluocinolone Acetonide Oil.11 mg/mL · a-s medication solutions
- Derma-Smoothe/FS.11 mg/mL · royal pharmaceuticals, llc
- Synalar.25 mg/g · medimetriks pharmaceuticals, inc.
- Retisert.59 mg · bausch & lomb incorporated
- Iluvien.19 mg · ani pharmaceuticals, inc.
- DERMOTIC.11 mg/mL · royal pharmaceuticals
- Flac Otic Oil.11 mg/mL · patrin pharma, inc.
- YUTIQ.18 mg · ani pharmaceuticals, inc.
Canada
- SYNALAR
- FLUODERM CRM
- DERMA SMOOTHE/FS
- DERMOTIC OIL EAR
- RETISERT
- FLUODERM ONT